Odyssey Therapeutics (NASDAQ:ODTX) Now Covered by Oppenheimer

Research analysts at Oppenheimer initiated coverage on shares of Odyssey Therapeutics (NASDAQ:ODTX) in a research note issued on Tuesday, MarketBeat reports. The brokerage set an “outperform” rating and a $40.00 price target on the stock. Oppenheimer’s target price points to a potential upside of 135.85% from the stock’s current price.

Several other brokerages also recently weighed in on ODTX. TD Cowen assumed coverage on Odyssey Therapeutics in a research note on Tuesday. They set a “buy” rating on the stock. Wall Street Zen upgraded Odyssey Therapeutics to a “hold” rating in a research note on Saturday, May 16th. Three equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $40.00.

Odyssey Therapeutics Stock Down 0.3%

Shares of NASDAQ:ODTX opened at $16.96 on Tuesday. Odyssey Therapeutics has a 12-month low of $15.35 and a 12-month high of $20.30.

Insider Buying and Selling at Odyssey Therapeutics

In related news, Director Nan (Ln) Li acquired 1,111,111 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was acquired at an average price of $18.00 per share, with a total value of $19,999,998.00. Following the acquisition, the director directly owned 3,333,516 shares in the company, valued at $60,003,288. This represents a 50.00% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Shelley Chu acquired 11,111 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was bought at an average cost of $18.00 per share, with a total value of $199,998.00. Following the acquisition, the director owned 11,111 shares in the company, valued at approximately $199,998. This trade represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders have bought 4,183,777 shares of company stock worth $75,319,986.